Poster Presentations: Wednesday, November 3, 2010 |

Antibiotic-Resistant Cytomegalovirus Infection Following Oral Valganciclovir Prophylaxis in Lung Transplant Recipients FREE TO VIEW

Linda J. Stuckey, PharmD; Anish Wadhwa, MD; Daniel Kaul, MD; Kristy Bauman, MD; Vibha N. Lama, MBBS; MeiLan K. Han, MD; Tammy C. Ojo, MD; Kevin R. Flaherty, MD; Cathy Bartos, RN; Ros Florn, RN; Raja S. Mahidhara, MD; Kevin M. Chan, MD
Author and Funding Information

Univeristy of Michigan, Ann Arbor, MI

Chest. 2010;138(4_MeetingAbstracts):546A. doi:10.1378/chest.10964
Text Size: A A A
Published online


PURPOSE: Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplant recipients. Oral valganciclovir(Val) has excellent bioavailability and is used for both treatment and prevention of CMV infection. Herein, we describe outcomes of CMV infection(Inf) and disease(Dis) in our lung transplant population using Val.

METHODS: Retrospective evaluation of CMV at risk lung transplant recipients surviving > 30 days between March 2008&March 2010. Oral Val prophylaxis was initiated at 900 mg daily for 6 months in CMV donor(D)+ and recipient(R)- patients. D or R + patients received Val for 3 months. Doses were adjusted for renal insufficiency and leukopenia. CMV Inf was defined as BAL shedding without CMV syndrome or viremia. CMV Dis was defined as viremia or tissue invasion on biopsy.

RESULTS: 65 patients were included. Median follow up was 298 days(range 57-791). CMV at risk groups D+/R-(n=15), D+/R+(n=26), D-/R+(n=11), D-/R-(n=13). CMV Inf or Dis occurred in 17 patients. D-/R- patients had 0 events, D-/R+ 1 event, D+/R- 3 events. 50%(n=13) of the D+/R+ group had a CMV event which was statistically > D-/R- group (p=0.0057). 3 patients developed Val resistance. 1) D+/R-, IPF, POD 80, UL 97 mutation, intermittent Val due to leukopenia. 2) D+/R+, sarcoid, POD 119, UL 97, intermittent Val due to leukopenia. 3) D+/R+, CF, POD 159, UL 97&UL 54, foscarnet&cidofovir resistance. Time to Inf/Dis was shorter(median 119 vs 224 days,p=0.016)& viral load greater(54,500 copies/ml vs 14,750 copies/ml,p=0.23) in the Val resistant vs susceptible groups.

CONCLUSION: Oral Val is effective in the majority of CMV at risk lung transplant patients. CMV D+/R+ recipients are at greater risk of CMV Inf or Dis than previously described. Intermittent use of Val due to leukopenia or poor Val absorption can lead to Val resistance resulting in increased patient morbidity.

CLINICAL IMPLICATIONS: Intermittent dosing of Val or malabsorption of the medication, perhaps in the CF population can result in increased Val resistance.

DISCLOSURE: Anish Wadhwa, No Financial Disclosure Information; No Product/Research Disclosure Information

12:45 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Feverish illness in children: assessment and initial management in children younger than 5 years.
National Collaborating Centre for Women's and Children's Health | 8/28/2009
American Academy of Ophthalmology | 6/5/2009
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543